Your email address is safe with us. View our Privacy policy.
New Alzheimer's target identified
Dr. Lennart Mucke and colleagues at the Gladstone Institute of Neurological Disease, using a mouse model, made the discovery.
Enkephalins are part of the endogenous opioid system, which modulates learning and memory and other brain functions.
"The enkephalin pathway is an intriguing candidate for us because it is involved in many functions that are affected by Alzheimer's and other neurodegenerative diseases," said Mucke, the institute's director. "We were not sure, though, whether it contributed causally to the disease or acts as a compensatory mechanism.
"Our results indicate that the high levels of enkephalins may contribute to cognitive impairments in AD patients," said Mucke. "Although these are early results, they are encouraging and may lead the way to a new AD therapy based on limiting enkephalin production or signaling."
The study that included William Meilandt, Gui-Qiu Yy, Jeannie Chin, Erik Roberson, Jorge Palop, Tiffany Wu and Kimberly Scearce-Levie appears in the Journal of Neuroscience.
Copyright 2008 by United Press International
This news arrived on: 05/08/2008
Printer Friendly Version | Send this page to a friend | Post Comment
Rate This Story:
Great - 5 - 4 - 3 - 2 - 1 - Bad
Posted Comments:
Comment archive | Comment FAQ's
 |
 |
View Science & Technology ezine stories by date or visit the complete archive |
The ArcaMax Politics channel is one of 70 content categories offered by ArcaMax Publishing on this ... |
ArcaMax Dating
